Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Acorda Therapeutics Inc ACORQ

Healthcare Biotechnology
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa... see more

Recent & Breaking News (OTCPK:ACORQ)

Activists Gonna Activate: Hedge Funds Send Letters To Acorda, Taubman Centers Boards

Benzinga.com  August 7, 2017

18 Biggest Mid-Day Gainers For Monday

Benzinga.com  August 7, 2017

Acorda Provides Financial and Pipeline Update for Second Quarter 2017

Business Wire July 27, 2017

Acorda Second Quarter 2017 Update Webcast/Conference Call Scheduled for July 27, 2017

Business Wire July 13, 2017

Stocks Under Scanner in the Biotech Space -- Achillion Pharma, Kite Pharma, Acorda Therapeutics, and Tesaro

PR Newswire July 6, 2017

Acorda Submits New Drug Application to U.S. Food and Drug Administration for INBRIJATM (CVT-301, Levodopa Inhalation Powder)

Business Wire June 29, 2017

22 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  June 6, 2017

Acorda Presenting New Tozadenant Data at 2017 MDS Congress

Business Wire June 6, 2017

CVT-301 Phase 3 Data Showed Significantly Improved Motor Function During OFF Periods in Parkinson’s Disease

Business Wire June 5, 2017

Acorda to Present at the Goldman Sachs Healthcare Conference

Business Wire May 31, 2017

Biotech Stocks on Investors' Radar -- Achillion Pharma, Acorda Therapeutics, Aralez Pharma, and Regulus Therapeutics

PR Newswire May 26, 2017

Acorda to Present New INBRIJA™ (Levodopa Inhalation Powder) Phase 3 Data at Upcoming MDS Congress

Business Wire May 18, 2017

Acorda to Present at the Deutsche Bank 42nd Annual Healthcare Conference

Business Wire May 2, 2017

Acorda Expands Alexa Skill Offering for Parkinson’s Awareness Month

Business Wire April 28, 2017

Acorda Provides Financial and Pipeline Update for First Quarter 2017

Business Wire April 27, 2017

Acorda to Host Conference Call to Discuss First Quarter 2017 on April 27, 2017

Business Wire April 13, 2017

ACORDA NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics Inc. To Contact The Firm

PR Newswire April 7, 2017

Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs

Business Wire April 5, 2017

Mid-Afternoon Market Update: Dow Drops 50 Points; TRC Companies Shares Spike Higher

Benzinga.com  March 31, 2017

U.S. District Court Issues Decision to Invalidate Four AMPYRA Patents; Company Will Appeal Ruling

Business Wire March 31, 2017